Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04920617 |
| Title | DPX-Survivac, Alone or in Combination With Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Acronym | VITALIZE |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | NZL | FRA | ESP | CAN | AUS |